PMID- 8756369
OWN - NLM
STAT- MEDLINE
DCOM- 19960913
LR  - 20111117
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 78
IP  - 4
DP  - 1996 Aug 15
TI  - Malignant melanoma: relationship of the human leukocyte antigen class II gene 
      DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or 
      II.
PG  - 758-63
AB  - BACKGROUND: Melanoma patients who carry the human leukocyte antigen (HLA) Class 
      II allele DQB1*0301 have an increased frequency of metastases at presentation 
      compared with those lacking HLA-DQB1*0301. This study was designed to determine 
      whether HLA-DQB1*0301 is associated with an increased risk of recurrence in 
      melanoma patients presenting with American Joint Committee on Cancer (AJCC) Stage 
      I or II (localized) disease. METHODS: Molecular oligotyping of HLA-DQ genes was 
      performed for 259 patients with AJCC Stage I or II melanoma. Rate of disease 
      recurrence was determined by retrospective review and prospective follow-up. 
      Kaplan-Meier analysis, log rank, and proportional hazard (Cox) comparison were 
      performed. RESULTS: Median follow-up was 24 months. Minimum follow-up was 6 
      months. Although HLA-DQB1*0301-positive and -negative patients were balanced with 
      regard to standard melanoma prognostic factors (primary tumor thickness, level of 
      invasion, presence of ulceration, anatomic location, and sex), 
      HLA-DQB1*0301-positive patients were more likely to develop locally recurrent, 
      regional, or distant metastatic melanoma during follow-up (actuarial median 
      disease free survival 48 months [DQB1*0301-positive patients] vs. 97 months 
      [DQB1*0301-negative patients]; log rank P = 0.0002). HLA-DQB1*0301 status, in 
      addition to primary tumor thickness, was an independent prognostic indicator in 
      these patients (Cox multivariate P = 0.02). CONCLUSIONS: Patients presenting with 
      localized melanoma who carry HLA-DQB1*0301 are at an increased risk of developing 
      recurrent disease compared with stage-matched patients who lack this allele. 
      HLA-DQB1*0301 is a genomic marker which independently identifies melanoma 
      patients in whom recurrence is more likely, and is potentially useful in 
      selecting those most likely to benefit from adjuvant therapy.
FAU - Lee, J E
AU  - Lee JE
AD  - Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 
      Houston 77030, USA.
FAU - Lu, M
AU  - Lu M
FAU - Mansfield, P F
AU  - Mansfield PF
FAU - Platsoucas, C D
AU  - Platsoucas CD
FAU - Reveille, J D
AU  - Reveille JD
FAU - Ross, M I
AU  - Ross MI
LA  - eng
GR  - CA16672/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
SB  - IM
MH  - Alleles
MH  - Female
MH  - Follow-Up Studies
MH  - HLA-DQ Antigens/*genetics
MH  - HLA-DQ beta-Chains
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Male
MH  - Melanoma/*genetics/pathology
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*genetics/pathology
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
EDAT- 1996/08/15 00:00
MHDA- 2000/06/20 09:00
CRDT- 1996/08/15 00:00
PHST- 1996/08/15 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1996/08/15 00:00 [entrez]
AID - 10.1002/(SICI)1097-0142(19960815)78:4<758::AID-CNCR11>3.0.CO;2-U [pii]
AID - 10.1002/(SICI)1097-0142(19960815)78:4<758::AID-CNCR11>3.0.CO;2-U [doi]
PST - ppublish
SO  - Cancer. 1996 Aug 15;78(4):758-63. doi: 
      10.1002/(SICI)1097-0142(19960815)78:4<758::AID-CNCR11>3.0.CO;2-U.